A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma

Biomaterials

Volumn 31, Issue 36, 2010, Pages 9535-9543

  Zhang, Chao ^a,b   Peng, Yi ^a   Wang, Fengchao ^a   Tan, Xu ^a   Liu, Nan ^a   Fan, Song ^a   Wang, Dechun ^a   Zhang, Lilong ^a   Liu, Dengqun ^a   Wang, Tao ^a   Wang, Shaojun ^a   Zhou, Yue ^b   Su, Yongping ^a   Cheng, Tianmin ^a   Zhuang, Zhengping ^c   Shi, Chunmeng ^a  

^a Burns and Combined Injury   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Cantharidin derivative; Doxorubicin; Enhanced chemotherapy; Metastasis; PP2A inhibitor; Sarcoma

Indexed keywords

CANTHARIDIN DERIVATIVE; DOXORUBICIN; ENHANCED CHEMOTHERAPY; METASTASIS; PP2A INHIBITOR; SARCOMA;

CELL CULTURE; CELL DEATH; CHEMOTHERAPY; PATHOLOGY; STEM CELLS; TOXICITY;

TUMORS;

CANTHARIDIN; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG SYNTHESIS; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; LUNG METASTASIS; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOMA; STEM CELL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CANTHARIDIN; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOXORUBICIN; HUMANS; MESENCHYMAL STEM CELLS; MULTIPOTENT STEM CELLS; NEOPLASM METASTASIS; RATS; SARCOMA; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

COLEOPTERA; HEXAPODA; RATTUS;

EID: 78149412422     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.08.059     Document Type: Article

References (26)

1. Liu D., Chen Z. The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem 2009, 9:392-396.
2. Hart M.E., Chamberlin A.R., Walkom C., Sakoff J.A., McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 2004, 14:1969-1973.
3. Lu J., Kovach J.S., Johnson F., Chiang J., Hodes R., Lonser R., et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 2009, 106:11697-11702.
4. Honoki K. Do stem-like cells play a role in drug resistance of sarcomas?. Expert Rev Anticancer Ther 2010, 10:261-270.
5. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846.
6. Kamohara Y., Haraguchi N., Mimori K., Tanaka F., Inoue H., Mori M., et al. The search for cancer stem cells in hepatocellular carcinoma. Surgery 2008, 144:119-124.
7. Shi C., Mai Y., Zhu Y., Cheng T., Su Y. Spontaneous transformation of a clonal population of dermis-derived multipotent cells in culture. In Vitro Cell Dev Biol Anim 2007, 43:290-296.
8. Tolar J., Nauta A.J., Osborn M.J., Panoskaltsis Mortari A., McElmurry R.T., Bell S., et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007, 25:371-379.
9. Miura M., Miura Y., Padilla-Nash H.M., Molinolo A.A., Fu B., Patel V., et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
10. Yamate J., Ogata K., Yuasa T., Kuwamura M., Takenaka S., Kumagai D., et al. Adipogenic, osteogenic and myofibrogenic differentiations of a rat malignant fibrous histiocytoma (MFH)-derived cell line, and a relationship of MFH cells with embryonal mesenchymal, perivascular and bone marrow stem cells. Eur J Cancer 2007, 43:2747-2756.
11. Tasso R., Augello A., Carida M., Postiglione F., Tibiletti M.G., Bernasconi B., et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis 2009, 30:150-157.
12. Balamuth N.J., Womer R.B. Ewing's sarcoma. Lancet Oncol 2010, 11:184-192.
13. Krikelis D., Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010, 10:249-260.
14. Mendenhall W.M., Indelicato D.J., Scarborough M.T., Zlotecki R.A., Gibbs C.P., Mendenhall N.P., et al. The management of adult soft tissue sarcomas. Am J Clin Oncol 2009, 32:436-442.
15. Schmitt T., Kasper B. New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. Expert Rev Anticancer Ther 2009, 9:1159-1167.
16. Velupillai P., Sung C.K., Tian Y., Dahl J., Carroll J., Bronson R., et al. Polyoma virus-induced osteosarcomas in inbred strains of mice: host determinants of metastasis. PLoS Pathog 2010, 6:e1000733.
17. Shi C., Cheng T. Effects of acute wound environment on neonatal rat dermal multipotent cells. Cells Tissues Organs 2003, 175:177-185.
18. Wada T., Akiyoshi T., Nakamura Y., Tsuji H. Colony growth of cells from primary breast carcinoma in soft agar culture. Jpn J Surg 1984, 14:212-216.
19. Czeczuga-Semeniuk E., Wolczynski S., Dabrowska M., Dzieciol J., Anchim T. The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells. Folia Histochem Cytobiol 2004, 42:221-227.
20. Liu N., Fang H., Li Y., Xu W. Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment. Curr Med Chem 2009, 16:4869-4888.
21. Lettini A.A., Guidoboni M., Fonsatti E., Anzalone L., Cortini E., Maio M. Epigenetic remodelling of DNA in cancer. Histol Histopathol 2007, 22:1413-1424.
22. Noteborn M.H. Proteins selectively killing tumor cells. Eur J Pharmacol 2009, 625:165-173.
23. Gascoigne K.E., Taylor S.S. How do anti-mitotic drugs kill cancer cells?. J Cell Sci 2009, 122:2579-2585.
24. Valensin S., Ghiron C., Lamanna C., Kremer A., Rossi M., Ferruzzi P., et al. KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?. BMC Cancer 2009, 9:196.
25. Eichhorn P.J., Creyghton M.P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009, 1795:1-15.
26. Zhuang Z., Lu J., Lonser R., Kovach J.S. Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell Cycle 2009, 8:3303-3306.